Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers (Q37481367)

20 August 2017

1 reference

title

Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers (English)

1 reference

20 August 2017

0 references

0 references

Pierre Bischoff

1

1 reference

20 August 2017

Anais Altmeyer

series ordinal

2

1 reference

20 August 2017

Francis Dumont

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

Expert Opinion on Therapeutic Patents

20 August 2017

1 reference

20 August 2017

19

1 reference

20 August 2017

5

1 reference

20 August 2017

643-662

1 reference

Radiation oncology: a century of achievements.

20 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

The concurrent chemoradiation paradigm--general principles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Chemical radiosensitizers for use in radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Current concepts for the combined treatment modality of ionizing radiation with anticancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Antimetabolite radiosensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Current status of chemoradiotherapy for gastric cancer in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

IPdR: a novel oral radiosensitizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Recent developments to improve the efficacy of cytotoxic nucleoside analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Clofarabine acts as radiosensitizer in vitro and in vivo by interfering with DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Combined modality treatment of glioblastoma multiforme: the role of temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

The resurgence of platinum-based cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Combining radiation with oxaliplatin: a review of experimental results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Topoisomerase I inhibitors: camptothecins and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Broken beyond repair. Damaging DNA in glioblastoma cells with radiation and camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Role of cell cycle in mediating sensitivity to radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Hypoxic radiosensitization: adored and ignored

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Bioreductive drugs: from concept to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Evaluation of HIF-1 inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Targeting hypoxia cell signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Hypoxia, HIF1 and glucose metabolism in the solid tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Design of hypoxia-targeting drugs as new cancer chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Design, synthesis, and radiosensitizing activities of sugar-hybrid hypoxic cell radiosensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Radiosensitization by nitric oxide at low radiation doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Hypoxic tumor cell radiosensitization through nitric oxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Transport and peripheral bioactivities of nitrogen oxides carried by red blood cell hemoglobin: role in oxygen delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Regulation of HIF-1alpha stability through S-nitrosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Tirapazamine: a novel agent targeting hypoxic tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

Cancer stem cells in radiation resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902824172

10.1517/13543770902824172

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference